Kaitlin Mrksich

Kaitlin Mrksich

Auto-generated profile, based on publicly available information

Kaitlin Mrksich

Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Nano Letters
Verified
Journal Article
Closed access
EHEmily L. Han
Emily L. Han
STSophia Tang
Sophia Tang
DKDongyoon Kim
Dongyoon Kim
AMAmanda M. Murray
Amanda M. Murray
KSKelsey L. Swingle
Kelsey L. Swingle
MMMichael Mitchell
Michael Mitchell

24 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarshall S. Padilla
Marshall S. Padilla
KMKaitlin Mrksich
Kaitlin Mrksich
YWYiming Wang
Yiming Wang
RHRebecca Haley
Rebecca Haley
JLJacqueline J. Li
Jacqueline J. Li
MMMichael Mitchell
Michael Mitchell
Lipid nanoparticles (LNPs) are the preeminent non-viral drug delivery vehicle for mRNA-based therapies. Immense effort has been placed on optimizing the ionizable lipid (IL) structure, which contains an amine core conjugated to lipid tails, as small molecular adjustments can result in substantial changes in the overall efficacy of the resulting LNPs. However, despite some advancements, a major barrier for LNP delivery is endosomal escape. Here, we develop a platform for synthesizing a class of branched ILs that improve endosomal escape. These compounds incorporate terminally branched groups that increase hepatic mRNA and ribonucleoprotein complex delivery and gene editing efficiency as well as T cell transfection compared to non-branched lipids. Through an array of complementary experiments, we determine that our lipid architecture induces greater endosomal penetration and disruption. This work provides a scheme to generate a class of ILs for both mRNA and protein delivery.

30 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RPRohan Palanki
Rohan Palanki
JRJohn S. Riley
John S. Riley
SBSourav K. Bose
Sourav K. Bose
VLValerie Luks
Valerie Luks
ADApeksha Dave
Apeksha Dave
WPWilliam H. Peranteau
William H. Peranteau
Monogenic blood diseases are among the most common genetic disorders worldwide. These diseases result in significant pediatric and adult morbidity, and some can result in death prior to birth. Novel ex vivo hematopoietic stem cell (HSC) gene editing therapies hold tremendous promise to alter the therapeutic landscape but are not without potential limitations. In vivo gene editing therapies offer a potentially safer and more accessible treatment for these diseases but are hindered by a lack of delivery vectors targeting HSCs, which reside in the difficult-to-access bone marrow niche. Here, we propose that this biological barrier can be overcome by taking advantage of HSC residence in the easily accessible liver during fetal development. To facilitate the delivery of gene editing cargo to fetal HSCs, we developed an ionizable lipid nanoparticle (LNP) platform targeting the CD45 receptor on the surface of HSCs. After validating that targeted LNPs improved messenger ribonucleic acid (mRNA) delivery to hematopoietic lineage cells via a CD45-specific mechanism in vitro, we demonstrated that this platform mediated safe, potent, and long-term gene modulation of HSCs in vivo in multiple mouse models. We further optimized this LNP platform in vitro to encapsulate and deliver CRISPR-based nucleic acid cargos. Finally, we showed that optimized and targeted LNPs enhanced gene editing at a proof-of-concept locus in fetal HSCs after a single in utero intravenous injection. By targeting HSCs in vivo during fetal development, our Systematically optimized Targeted Editing Machinery (STEM) LNPs may provide a translatable strategy to treat monogenic blood diseases before birth.

23 October 2025 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MPMarshall S. Padilla
Marshall S. Padilla
SSSarah J. Shepherd
Sarah J. Shepherd
AHAndrew R. Hanna
Andrew R. Hanna
MKMartin Kurnik
Martin Kurnik
XZXujun Zhang
Xujun Zhang
MMMichael Mitchell
Michael Mitchell

22 July 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
RPRohan Palanki
Rohan Palanki
EHEmily L. Han
Emily L. Han
AMAmanda M. Murray
Amanda M. Murray
RMRohin Maganti
Rohin Maganti
STSophia Tang
Sophia Tang
MMMichael Mitchell
Michael Mitchell
Our work elucidates the importance of LNP formulation parameters, including microfluidic flow rate and organic excipient identity, for in vivo gene editing and presents an optimized delivery platform for the treatment of metabolic liver disease.

20 January 2026 in ACS Nano
Verified
Journal Article
Closed access
EHEmily L. Han
Emily L. Han
DKDongyoon Kim
Dongyoon Kim
AMAmanda M. Murray
Amanda M. Murray
KMKaitlin Mrksich
Kaitlin Mrksich
AHAlex G. Hamilton
Alex G. Hamilton
MMMichael Mitchell
Michael Mitchell